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Abstract Albuterol, a selective beta-adrenergic agonist, has
been used experimentally in combination with exercise
therapy in a few inherited neuromuscular disorders to increase
muscle strength andmuscle volume.We report on a 9-year-old
boy with central core disease and mitochondrial dysfunction
due to compound heterozygous RYR1 mutations receiving
albuterol treatment for 1 year. Throughout the period of
albuterol administration, the patient underwent an aerobic
exercise regime of training sessions three times a week that
lasted 20 min each. No side effects of albuterol use were
seen. Significant clinical progress, including self care, sitting
up, raising arms above the shoulders, independent feeding,
and better speech and writing were observed compared with
minimal development of these abilities in the previous years
on physiotherapy. Improved forced expiratory volume in 1 s
(FEV1) score was detected and increased muscle strength
was noted: progress was measured using various functional
tests and assessment scales. The only complication observed
was a mild progression of the joint contractures, possibly due
to an unbalance between the flexor and extensor muscula-
ture. In general, in this pilot study in a complex case of
metabolic myopathy our patient has shown promising results
following albuterol treatment and aerobic exercise therapy.
Abbreviations
CMAS Childhood Myositis Assessment Scale
FSHD Fascioscapulohumeral muscular dystrophy
Introduction
Inactivity in patients with muscle disease in combination
with a primary or secondary mitochondrial dysfunction
might cause a further decrease in muscle mass and muscle
tone and a further decrease in adenosine triphosphate (ATP)
production (Finsterer 2004). This deteriorating cascade of
restriction in mobility leads to diminished function and
decrease in quality of life (QOL) by increasing isolation
(Morava et al. 2006). Patients with exercise intolerance and
muscle weakness could benefit from regular exercise.
Benefits could include improvement of activity, general
fitness, and some increase in muscle strength. However,
there is little evidence for the benefit of exercise in
congenital myopathies. In mitochondrial disorders, strength
training could be even deleterious due to increased lactate
production and muscle damage. On the other hand, aerobic
training in these patients appears to be beneficial. The
results in patients carrying highly heteroplasmic mitochon-
drial DNA mutations are still controversial; some studies
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report a relative increase of mutation frequency in a second
biopsy after a fitness therapy period of 6 months to 1 year
(Janssen et al. 2006, Phoenix et al. 2006).
Recently, albuterol has been used experimentally in a few
inherited neuromuscular disorders in order to increase muscle
strength and muscle volume. Albuterol is a selective beta-
adrenergic agonist used to control asthma. Albuterol is
contraindicated in case of hypertension, heart disease,
hyperthyroidism, and diabetes mellitus, restricting the use of
the drug in endocrine and metabolic myopathies. In faciosca-
pulohumeral muscular dystrophy (FSHD; OMIM 158900),
the combined use of albuterol and exercise training had a
positive effect on muscle strength and volume, with an
increase in the lean body mass (Kissel et al. 1998, 2001). In
patients diagnosed with spinal muscular atrophy (SMA;
OMIM 253300/253400/253550/271150), the use of albuterol
leads to a significantly higher myometry, improvement in the
forced vital capacity (FVC), and increase in lean body mass
without adverse effects (Hirano 2003; Kinali et al 2002).
Multi/minicore myopathy (OMIM 117000) is a congenital
myopathy presenting with generalized muscle hypotonia,
decreased muscle strength, decreased deep tendon reflexes,
and a stagnatory muscle disease. Many patients eventually
show a very slow clinical improvement, but in some cases,
difficulties increase over time (Jungbluth 2007). Most patients
have contractures in the knees, hips, and shoulders, hindering
eventual exercise, and children with the disorder are prone to
frequent respiratory infections and hypoventilation. Apart
from the ryanodine 1 (RYR1; gene ID 6261) gene, another
gene is implicated in the disease. If the selenoprotein N
(SEPN; gene ID 57190) gene is impaired, patients are more
likely to develop pulmonary problems. This is not a
prominent feature in RYR1-related multi/minicore myopathy
(Jungbluth 2007): due to mutations to the ryanodine receptor
1 (RYR1; gene ID 6261) gene, leakage of the ryanodine
receptor may occur, causing chronic elevation of cytosolic
calcium (Gommans et al. 2002). In the cells’ periphery,
plasma membrane calcium-channel (Ca2+) pumps and
sodium (Na+)/Ca2 exchangers remove this calcium, whereas
mitochondria and sarcoplasmic reticulum Ca2+adenosine
triphosphate (ATP)ase (SERCA) are responsible for nearly
all removal from the center of the cell (Gommans et al.
2002). Due to absence of pumps and exchangers in the
center of the cell, there is elevated calcium, which causes
most of the damage to mitochondria. Therefore, patients with
multi/minicore myopathy might present with mitochondrial
dysfunction (Wortmann et al. 2009), in turn causing lower
ATP synthesis, which can lead to disorganization of the
myofibrils, leading to pathologic central cores and muscle
weakness (Loke and MacLennan 1998). Albuterol increases
the level of the fast-twitch isoform of SERCA (SERCA1a)
(Zhang et al. 1996). Changes in the levels of SERCA
proteins, particularly SERCA1a, could account for increasing
calcium uptake rate observed in homogenates of muscles
from the albuterol-treated animals (Zhang et al. 1996). This
would increase the ability to clear intracellular calcium,
resulting in improved muscle function and less damage to
mitochondria.
In previous studies, the experimental use of albuterol in this
patient group resulted in increased Medical Research Council
(MRC) scores, myometry, and FVC in patients receiving a
6-month trial period with regular physiotherapy (Messina et al.
2004). However, no data on the metabolic parameters of
these patients were reported. In adults with a metabolic
myopathy due to mitochondrial DNA mutations, aerobic
exercise training has been used with positive outcome
(Cejudo et al. 2005; Jeppesen et al. 2006; Joseph et al.
2006; Taivassalo et al. 2006). Here we describe the clinical
course of a patient diagnosed with central-core myopathy and
mitochondrial dysfunction on aerobic exercise and albuterol
treatment. This is the same patient as the one reported in
2009 by Wortmann and colleagues (Wortmann et al. 2009).
Patient and methods
Treatment protocol
After approval of the ethical commission and obtaining
informed consent, albuterol was administered to our patient
four times a day for 1 year at a dosage of 2 mg each time. To
monitor the occurrence of possible cardiac side effects,
cardiological evaluation consisting of electrocardiogram
(ECG) and cardiac echography took place every 3 months
(T0, T1, T2, T3, and T4). In addition, weekly measurements of
heart rate, blood pressure, and blood glucose values were
performed and the patient’s weight monitored. In addition to
administration of the drug, the patient underwent 20-min
aerobic training exercise three times a week. This training
was aimed at the quadriceps muscles, flexors and extensor of
the hip and lower arm, biceps brachii muscles, and
musculature of the shoulder’s rotator cuff. The maximum
number of repeats for each exercise was established by the
physiotherapist. Apart from these protocol-based sessions,
functional activities were performed daily (practicing getting
dressed, throwing, catching, “soccer”, sitting upright, rolling
over in bed, and putting shoes on). To evaluate progress, the
patient underwent physiotherapeutic evaluation at T0, T2, and
T4. During these evaluations, he was evaluated clinically.
The motometrical instruments used to document his progress
included the functional scale according to Scott, modified by
Bäckman, which is a measurement tool for muscle function
(Bäckman 1988; Scott et al. 1982); the forced expiratory
volume in 1 s (FEV1) as a measurement of respiratory
function associated with increasing strength of respiratory
muscles, the Childhood Myositis Assessment Scale (CMAS)
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for quantitative evaluation of muscle function (Huber et al.
2004), and the Jamar dynamometer for assessment of force
for various muscle groups (Trutschnigg et al. 2008).
Concerning the functional scale according to Scott et al.
(1982) and the CMAS, it should be taken into account that
some items could not be scored because of the patient’s
inability to stand up, which is a prerequisite for these items.
Therefore, the patient could never be expected to reach the
maximum score of 52. The scales were merely documented
to quantify the patient’s increasing functionality.
Patient
The patient was the second child of nonconsanguineous parents
who was born after an uneventful pregnancy of 42 weeks. At
birth, early findings comprised congenital hypotonia, low facial
expression, and inverted feet. He was diagnosed with swallow-
ing problems and gastroesophageal reflux. Dysmorphic fea-
tures included brachyturricephaly, low-set ears, hypermetropia,
faciesmyopathica, and hyperlaxity with arachnodactyly. Due to
positive family history of minicore myopathy (his sister died
with this condition at age 5 due to aspiration), an early muscle
biopsy was performed. The initial histological findings
suggested a possible multi/minicore disease. The patient
developed chronic lactic acidemia (lactate 2.3–4 mmol/l, C:
<2.1 mmol/l), 3-methylglutaconic aciduria (80 μmol/l, C:
<18 μmol/mmol creatinine), and recurrent hypoglycemic
episodes. Serum alanine levels (610 μmol/l, C: <450 μmol/l)
and creatine kinase (CK) levels (500–800 U/l, C: 180 U/l) were
moderately increased. No motor development was observed
with regular physiotherapy; for further clarification of the
diagnosis, a second muscle biopsy was performed at the age of
6 years. The biopsy results showed the characteristic picture of
central core disease: electron microscopy detected abnormal,
large mitochondria with crystalline inclusions and biochemical
evidence of severe mitochondrial dysfunction (Table 1).
Genetic studies including mitochondrial DNA sequencing,
sequencing of the nuclear-coded structural complexes I and III
genes, and POLG [polymerase (DNA directed) gamma; gene
ID 5428] mutation analysis were all normal. A compound
heterozygous RYR1 mutation in complementary DNA
(cDNA) [Val4849lle+1739–1741 dup, with premature stop
in position 610 (1741insATCAfsX29)] was found. The
parents were heterozygous carriers (Wortmann et al. 2009).
At age 9 years, while receiving regular physiotherapy, the boy
could not sit up, raise his arms above the level of the hips,
hold a pen, or stand due to his severe, generalized muscle
weakness and contractures. Further physical signs were
bilateral ptosis, facies myopathica with open mouth, and
kyphoscoliosis in addition to joint contractures, presenting
foremost in his hips and knees. He had no extraocular muscle
anomalies and no exercise-induced myalgia.
Results
At the age of 9 years (T0), the patient was unable to come
to a sitting position on his own and required assistance. He
could not raise his arms above his head and was unable to
keep his arms stretched before him. After the start of the
trial, improvements in functionality, independence, and
spontaneous movements were reported even after 6 weeks
without any complications or adverse events. At the time of
the physiotherapeutic evaluation at T2, (after 6 months of
therapy), there was a striking increase in strength, and the
patient followed the aforementioned training regime with
compliance and great enthusiasm. After 1 year of treatment,
at T4, significant further improvement became evident,
including several functional aspects in fine-motor develop-
ment (turning a key, holding a pen, brushing teeth), activity
(active movements throughout the day), and speech
development (decreasing dysarthria; less pronounced facies
myopathica and ptosis). At this point, he could sit up
straight without assistance, turn over in bed, and come to a
sitting position on his own from lying down. Also, he could
raise his arms above his head and even execute careful
punches on a boxing ball on a pole. Results for the
functional scale according to Scott et al. (1982), FEV1 and
Analyses performed Results
Biochemistry
ATP production nmol/h/mUCS (N 42–81) 4
Complex I mU/UCS (N 70–251) 58
Complex II mU/UCS (N 335–749) 312
Complex III mU/UCS (N 2200–6610) 725
Complex IV mU/UCS (N 810–3120) 483
Complex deficiencies I, II, III, IV
Genetics
Paternal mutation p. His581GlnfsX29 (exon 16)
Maternal mutation p.Val14849Ile (exon 101)
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CMAS are summarized in Table 2, showing increased
values for FEV1 and explosive strength. Scores for the
dynamometric tests, which illustrate a variable increase in
muscle force for different muscle groups, are displayed in
Table 3. Values for hip extensor muscles and ankle flexor
and extensor muscles could not be provided because of the
lack of sensitivity of the measurement instruments at low-
force levels. In the latter two muscle groups, the boy’s
inverted feet made dynamometric testing impossible.
The only complication observed was that after 1 year of
treatment, the boy’s flexion contractures increased 15° in his
hips and 30° in his knees, possibly correlating with the poor
knee extensor scores in Table 3. No abnormalities were
reported on the evaluations of the patient’s cardiac function,
heart rate, blood pressure, and blood glucose values. No
peculiar changes in body weight were noticed, apart from the
normal increase attributed to the patient growing.
Discussion
In summary, in this pilot study, a complex case of metabolic
myopathy (multi/minicore disease and mitochondrial dys-
function), our patient showed promising results on beta-
adrenergic-agonist treatment and exercise therapy. We report
the evident increase in muscle strength and independent
functionality as well as improved FEV1 after treatment with
albuterol combined with regular aerobic exercise. No serious
side effects were seen from the use of the beta agonist. An
important point in this accomplishment was the motivation
based on early therapeutic success in our patient. Unfortu-
nately, after an initial decrease of joint contractures in the
patient’s lower extremities, a gradual increase of contractures
was reported after 1 year of training, hindering self-care and
mobility. As an underlying explanation, we hypothesized the
lack of balance between flexor and extensor muscle force,
which could cause a passive decline in extensor muscle
force.
Aside from his multi/minicore myopathy, our patient had
chronic lactic acidemia, a shortened fasting tolerance, 3-
methyl glutaconic acidemia, and severe mitochondrial dys-
function, with deficiencies in the oxidative phosphorylation
complexes I, II, III, and IV. The metabolic abnormalities in
patients with central-core myopathy have been suggested to
be present due to the underlying cellular transport defect.
Central-core disease occurs due to autosomal recessive
mutations in the RYR1 gene and presents with abnormal
mitochondrial structure, detected by histology and electron
microscopy (central core due to abnormal mitochondrial
structure and localization), due to abnormal cellular calcium
transport. Normal calcium transport is essential for normal
mitochondrial function (Monnier et al. 2008).
Studies on aerobic exercise therapy have been reported
with promising results in several adult patients with
mitochondrial dysfunction (Cejudo et al. 2005; Joseph et
al. 2006; Messina et al. 2004; Taivassalo et al. 2006). Based
on the success in the complex patient reported here, one
should therefore hypothesize that anabolic therapy com-
bined with aerobic exercise might useful in treating patients
with certain types of mitochondrial myopathies. So far, to
Table 2 Motometric scores
Scott et al. 1982) FEV1 CMAS
T0 6 1,46 3
T2 9 1,81 12
T4 9 1,85 20
FEV1 forced expiratory value in 1 s, CMAS Childhood Myositis
Assessment Scale
Body part T0 T2 T4
Left Increase Increase
Shoulder abduction. 23 21 35 26 +39% 31 26 +30%
Elbow flexion ND ND 17 17 ND 22 17 +15%
Elbow extension 12 11 16 17 +43% 31 31 +170%
Hip flexion 31 22 47 53 +89% 62 62 +134%
Knee flexion 37 37 42 34 +24% 55 44 +34%
Knee extension 17 17 26 37 +85% 22 35 +68%
Right
Shoulder abduction 17 14 31 22 +71% 31 23 +74%
Elbow flexion ND ND 17 18 ND 17 22 +11%
Elbow extension 12 11 17 17 +48% 22 17 +70%
Hip flexion 17 17 84 55 +309% 93 80 +409%
Knee flexion 46 42 45 51 +9% 53 62 +31%
Knee extension 26 22 31 33 +33% 17 17 +29%
Table 3 Hand-held dynamome-
ter scores
Dynamometric scores for each
body half are recorded for each
of the physiotherapeutic
evaluations. Two measurements
were done at each point.
Changes in average values
compared with the first
measured value (T0, but T2 for
elbow flexors) are outlined in
the columns titled “Increase”
ND no data
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our knowledge, no prospective study has been performed in
children or adults using beta analogs in patients with a
primary mitochondrial defect and myopathy. The beneficial
effect of beta agonists in treating core myopathy patients
has been reported before (Messina et al. 2004). Although
mitochondrial function has not been reported in those
patients, considering a similar histopathological phenotype,
it seems unlikely that the beneficial effect of albuterol in
this cohort had a different basis than the beneficial effect
observed in this paper.
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